Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

(2014) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

(2013) M. A. Nauck et al.   DIABETOLOGIA

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

(2013) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Metformin use in chronic kidney disease: new evidence to guide dosing

(2013) W. G. Herrington et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Liraglutide-Induced Acute Kidney Injury

(2012) Yaman Kaakeh et al.   PHARMACOTHERAPY

Incretin Effects on  -Cell Function, Replication, and Mass: The human perspective

(2011) A. J. Garber   DIABETES CARE

Exenatide and renal failure

(2010) J. C. Ferrer-Garcia et al.   DIABETIC MEDICINE

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

(2010) Erin L St Onge et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

(2010) Alfonso López-Ruiz et al.   PHARMACY WORLD & SCIENCE

Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations

(2009) Douglas M. Fast et al.   AAPS Journal

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

(2009) Lisbeth V. Jacobsen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

Exenatide-Associated Ischemic Renal Failure

(2009) W. J. Weise et al.   DIABETES CARE

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

(2009) M. A. Bush et al.   DIABETES OBESITY & METABOLISM

Exenatide may aggravate moderate diabetic renal impairment: a case report

(2008) Odd Erik Johansen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE